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Abstract. Oral squamous cell carcinoma (OSCC) is one of the
major health problems in Sri Lanka and the disease is
associated with the habit of Betel Quid (BQ) chewing. Using
35k oligo microarrays, we analyzed the gene expression
profile of 15 Sri Lankan patients diagnosed with OSCCs and
pair-wised normal controls and correlated the findings with
the clinicopathological data. Following the recording of the
scanned array images and data analysis, results for selected
candidate genes were verified using QRT-PCR. Upon
analysis, a total of 263 genes [71 (27%) of unknown
functions previously not reported in OSCCs and 192 (73%)
of known functions] were found as differentially expressed
between tumors and controls. For the genes with known
functions, 66 (34%; such as COL4A1, MMP1, MMP3, PLAU,
SPARC and KRT19) were previously reported in OSCC and
for the remaining 126 (66%; such as CD47, APOL3, RRAGC,
BPIL1 and AZGP1) this is the first report in OSCCs.
Hierarchical clustering of the differentially expressed 263
genes grouped the samples into several clusters with the
larger one being dominated by tumors of stage 3 and 4. Two
cases (a verrucous SCC and an advanced SCC), did not cluster
with any of the other samples. We found two main biological
pathways (cell communication and integrin-mediated cell
adhesion) and 5 gene ontology categories (transcription
regulator activity, structural molecule activity, intracellular
signaling, cytoskeleton and signal transduction) of relevance
to the OSCCs examined. Results from the QRT-PCR verified
the results from the microarray experiment. This study
provides valuable information on gene expression profile of
OSCCs of habitual users of BQ from Sri Lanka. Of particular
interest were the list of genes of known and unknown
functions and the two biological pathways that we suggest as
candidate genes in oral cancers associated with BQ chewing
in Southeast Asia, in particular Sri Lanka. The suggested
candidate genes might be used as molecular biomarkers in
the early detection of the alarming problem of OSCCs in
Southeast Asia in association with BQ use. These findings
provide valuable information that might help in the selection
of possible biomarkers that can be used in early detection of
the alarming problem of oral cancer in Southeast Asia.
Introduction
Of the 500,000 new cases of oral squamous cell carcinomas
(OSCCs) reported annually, 62% occur in developing
countries with the highest rates reported in Sri Lanka and
other parts of Southeast Asia (1). In this part of the globe, an
estimated 600 million people are reported to chew areca nut
and betel quid (BQ) (2). In Sri Lanka, OSCC is linked to the
habit of BQ use (3). Areca nut (Areca catechu), the major
component of BQ, has been found to contain several alkaloids
that give rise to nitrosamines, some of which are carcinogenic
(4). It has been suggested that BQ-specific nitrosamines
(BQ-SNAs) may act as an adjunct to tobacco-specific
nitrosamines (TSNAs), implicated as an etiologic factor for
OSCCs (5). BQ-SNAs includes N-nitroso-guvacoline (NG)
and 3-(methyl-N-nitrosamino) propionitrile (MNPN) that is
also found in tobacco (6). In Sri Lanka, fresh areca nut, slaked
lime from seashells, betel leaf and dried (or processed) tobacco
are chewed, with the quid placed between the cheek mucosa,
the lower gingival and sulcus and sometimes retained during
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sleep (2). Buccal mucosa represents the primary site for OSCC
among betel quid chewers (2), contrary to tongue cancer,
which represents the primary site of cancers in Western
countries where cigarette smoking and heavy alcohol
consumption are the main causative factors (7). Molecular
mechanisms and steps of carcinogenesis in betel quid induced
OSCC may differ from those caused by cigarette smoking and
alcohol use (8).
Development of OSCC is a multi-step process involving
genes related to cell cycle, growth control, apoptosis, DNA
damage response and other cellular regulators (9).
Understanding the genetic processes and biological pathways
involved in the development of OSCC might lead to valuable
information that might improve disease classification, early
detection and diagnosis, as well as therapeutic planning and
drug development (10,11). Microarrays represent a promising
tool that makes it possible to explore the expression profile of
thousands of genes simultaneously, at the RNA level (12,13).
In the literature, there are several microarray studies on
OSCCs with promising findings (12-14). Although the
influence of life-style factors such as tobacco, alcohol use and
nutrition are important to consider in the causation of OSCCs,
there is a wide inter-individual difference(s) in susceptibility to
chemical carcinogens (15). Since BQ is associated with OSCC
development, we applied the 35k human oligo-microarrays
(produced and supplied by the Norwegian Microarray
Consortium, www.mikromatrise.no) to examine the gene
expression profile in 15 cases of OSCCs from Sri Lanka with
their corresponding pair-wise normal controls and correlated
the findings to patient's clinicopathological parameters.
Materials and methods
Patients. Primary samples (n=15) of OSCCs and their
corresponding pair-wised normal controls were acquired
from consecutive patients (average age 58.8 years; range 43 to
70; SD ± 8.68) with previously untreated OSCCs operated on
at the Department of Maxillofacial Surgery, University Dental
School at Peradeniya, Sri Lanka. The Ethics committee at the
University of Peradeniya approved the study and written
consent was obtained from the participating subjects. Normal
control samples were obtained either from the contralateral
side of the mouth or from an area that was at least 4 to 5 cm
away from the cancerous tissue and was macroscopically
normal. After surgery, tissue samples (malignant and normal)
were immediately submerged in the tissue storage and RNA
stabilization solution, RNAlater™ (Ambion, Inc., Woodlands,
TX, USA) and dispatched to the Department of Biomedicine at
the University of Bergen, where they were stored at -20˚C
until RNA purification and microarray experiments.
All tumors were staged following the 1987 UICC staging
system and had their histopathologic diagnosis confirmed by
two of the authors (SW/SOI) using either fresh frozen/or 10%
formalin-fixed, paraffin-embedded tissue sections stained with
haematoxylin and eosin (H&E). The tumors were histologically
graded into high, moderate or poorly differentiated carcinomas
(16). To rule out gene expression alterations because of
stromal cell contamination, we confirmed pathologically that
each tumor specimen contained ≥70% cancer cells by analysis
of the corresponding H&E-stained sections. For all the
patients, data on clinicopathological parameters, such as
information on betel quid chewing, were available (Table I).
Tissue samples and RNA exctraction. Total RNA was
extracted from both tumor and normal controls using TRIzol®
reagent (Gibco BRL, Carlsbad, CA, USA)/RNeasy Fibrous
Tissue kit (Qiagen Inc., Valencia, CA, USA) according to the
manufacturer's instructions. Quality and quantity of the RNA
were determined spectrophotometrically with a Beckman
DU®530 Life Science Spectrophotometer (Beckman Coulter,
Inc., Fullerton, CA, USA) and by an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA).
cDNA synthesis, hybridization and scanning. Synthesis and
labeling of the cDNA was carried out using Fairplay
Microarray Labelling kit (Stratagene, La Jolla, CA, USA),
following the manufacturer's instructions. Synthesized cDNA
was labeled with Cy™3 (normal cDNA) and Cy™5 (tumor
cDNA) monoreactive dyes (Amersham Biosciences, GE
Health Care) and samples were hybridized to the human
oligonucleotide microarrays containing 34,580 oligonucleotid
probes (The Human Genome Oligo Set Version 3.0; Operon
Biotechnologies Inc., Huntsville, AL, USA) representing
human genes and gene transcripts, printed on Corning Ultra
GAPS slides at the Norwegian Microarray Consortium
(www.mikromatrise.no). Labeled cDNA was hybridized on
the Ventana Discovery® XT System (Ventana Medical
Systems Inc., Tucson, AZ, USA) according to the
manufacturer's instructions. Slides were scanned by Agilent
DNA Microarray Scanner BA (Agilent Technologies, Palo
Alto, CA, USA) and the microarray data were stored as tiff
format images. The images were further analyzed with
GenePix Pro v5.0 (Molecular Devices Corp., Sunnyvale, CA,
USA) where bad spots and spots not found were flagged and
the final results containing all statistical values were stored as
a gpr-file.
Statistical analysis. Image quantization files obtained from
GenePix Pro were processed and merged into a gene
expression matrix using J-Express Pro software package
(version 2.6; www.molmine.com) (17). Each array was first
pre-processed separately by performing the following steps: i)
Spots flagged by Genepix (‘bad’, ‘absent’ or ‘not found’, -100,
-75 and -50, respectively) were filtered; ii) and in order to
avoid extreme ratios in spots where only one of the channels
had a significant signal, a flooring step was applied where
intensity values below 30 was set to 30, thereby eliminating
unwanted high ratios for spots with intensity near zero; iii) a
global lowess normalization was applied to all values left after
the filtering step. Thereafter, all in-array replicate spots were
merged by a median statistics and inserted into a gene
expression matrix where each row corresponds to a gene, each
column corresponds to a patient and each cell represents the
log (base 2) ratio value for the tumor versus the normal control
for one gene in one patient. Since the expression matrix will
contain cells with no values (missing values), genes for which
more than half of the patients (arrays) had no value were
removed. Missing values were set to zero, thus avoiding their
contribution in indicating up- or downregulation status of a
gene in tumor versus normal control. To prepare the
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expression matrix for array comparison, we applied scale
normalization to reduce differences in expression spread. For
finding a gene with a significant difference between tumor and
normal control, the relative difference in gene expression d
(i)=M(i)/(SE(i)+s) was used where M(i) is the mean log ratio
for gene i, SE(i) is the standard deviation of the gene's log
ratios and s is an added constant for all genes. In words, d(i) is
a student's t-statistics with a fudge factor s which corrects for
under-estimated variances resulting in a higher weight to high
average fold change versus low variance that can be justified
by the noisy nature of microarray experiments. In our case and
as suggested by Efron et al (18), a0 is set to a 90 percentile of
all gene standard errors SE(i).
Since all tumors were labeled with Cy5 and the
corresponding normal controls were labeled with Cy3, we
used as a control an additional set of hybridizations of 5 pairs
of experiments that included primary keratinocytes, dysplastic
oral epithelial cell line, OSCC cell line (SCC-25) and two
metastatic OSCC cell lines (OSC-2 and G6) that were
hybridized twice with a dye swap experiment using the same
arrays and identical experimental protocols. This was done to
find out whether genes found as differentially expressed were
due to dye swap effect or were due to the disease status. In our
case, we hypothesized that a gene-specific dye effect would
give genes with high s-scores in this matrix since a bias for one
gene will give a higher signal with one of the dyes and will
have this as a result. Therefore, we have chosen a very low
threshold of 0.5 for the s-score, which has resulted in a list of
1276 genes with a possible dye effect.
For the tumor expression matrix, we selected genes with an
s-score above 1.0 and obtained 461 genes as differentially
expressed either between the tumors and normal controls or
alternatively, as a result of the dye effect. To remove genes
affected by a dye effect, we removed all genes for which array
vendor had reported a possible dye effect and also genes with
an s-score above 0.5 in the dye swap expression matrix,
resulting in 263 genes that we believe are differentially
expressed between tumors and normal controls. We further
performed a permutation experiment and generated 1,000
permuted matrices. Each permuted matrix contains the 12034
genes in the original unfiltered data set and the permutation
was performed by flipping the sign of each column with a
probability of 0.5. Averaged over the 1,000 permuted matrices,
our analysis generated 0.47 genes per matrix with a d-score
above 1.0 resulting in a false discovery rate of 0.001.
To search for changed biological systems, mapping of the
selected genes was first done to a Gene Ontology (GO)
Directed Acyclic Graph (DAG) and thereafter comparison of
the number of the selected genes (263) in GO terms was done
to the number of the genes in a GO DAG based on all genes
left from low-level data preparation (12034 genes). We used
the Fisher-Irwin exact test to calculate a p-value for all GO
terms using a p-value cut-off at 0.05. All terms with less than
three selected genes and enrichment score (ratio of the relative
frequency of genes from a GO-term in the selected set to the
relative frequency of genes from the same term in the full set)
below 2 were removed. We searched for genes related to
the same biological pathway by performing a KEGG (19-21)
(Kyoto Encyclopedia of Genes and Genomes, www.KEGG.
com) analysis. We also used the Fisher-Irwin exact test to
find statistically significant pathways.
Hierarchical clustering, based on Pearson correlation and
average-linkage (WPGMA), was performed to cluster patients
with similar gene expression profiles.
Quantitative real-time RT-PCR. To validate gene expression
profile for selected candidate genes, real-time quantitative
RT-PCR was performed for nine genes: GJA1, MMP1,
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Table I. Clinicopathological data of the 15 patients included in the study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patients' clinicopathological data
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Sample no Tumor site TNM Stage Clinical appearance BQ Smoking Alcohol
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 Alveolus T2 N0 M0 2 Verrucous ++ ++ ++
2 Buccal T1 N0 M0 1 Exophytic ++ - -
3 Alveolus T2 N1 M0 3 Growth ++ - -
4 Floor T2 N1 M0 3 Growth ++ ++ ++
5 Buccal T4 N1 M0 4 Growth ++ - -
6 Alveolus T4 N1 M0 4 Growth ++ - -
7 Alveolus T2 N1 M0 3 Growth ++ ++ ++
8 Buccal T4 N1 M0 4 Exophytic/ulcer ++ ++ -
9 Lateral tongue T2 N0 M0 2 Growth - ++ ++
10 Buccal T2 N0 M0 2 White/red ulcer - + ++
11 Buccal T4 N1 M1 4 Growth ++ ++ ++
12 Alveolus T4 N0 M0 4 Growth ++ - -
13 Buccal T2 N0 M0 2 Verrucous ++ ++ +
14 Retromolar T4 N0 M0 4 Ulcer ++ - -
15 Buccal T2 N0 M0 2 White/ulcer ++ ++ +
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
TNM, tumor grading Broder's classification system; ++, regular (daily); +, occasionally; -, non-user.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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COL4A1, HAS3, CD47 and ANGPTL4 (all were upregulated),
S100A1, BPIL1 and WFDC2 (all were downregulated). These
genes were selected for verification because four of them
(GJA1, MMP1, COL4A1 and S100A1) were previously
reported in oral cancer, while the rest (HAS3, CD47,
ANGPTL4, BPIL1 and WFDC2) were not. Aliquots of the
same RNA (200-300 ng) used for the microarray hybridization
was also used for synthesis of the cDNA, performed with High
Capacity cDNA Archive kit (Applied Biosystems, Foster, CA),
following the manufacturer's instructions. Real-time PCR was
performed with probes for each gene (listed in Table II) using
the ABI 7900 HT (Applied Biosystems) and 384 well optical
plates (ABI). Each reaction contained 1 μl cDNA, 5 μl 2x
TaqMan Universal Master mix (Applied Biosystems), 0.5 μl
Taqman AOD probe and H2O to a final volume of 10 μl and
was run in triplicate. Cycling parameters were 95ºC for 10 min,
followed by 40 cycles at 95˚C for 15 sec and 60˚C for 1 min.
Serial diluted standards were run on the same plate and the
relative standard curve method was used to calculate the gene
expression as described elsewhere. ß-actin was used as an
endogenous normalization control to adjust for unequal
amounts of RNA.
Results
Among the 15 patients studied [3 (20%) females and 12
(80%) were males], 13 were regular betel quid chewers. Six
(40%) were both cigarette smokers and alcohol users, while
one (7%) patient was a regular smoker without other habits.
The two (14%) non-betel quid chewers smoked and drank
alcohol regularly. Two of the 15 cancers were verrucous
carcinomas while all the others were of squamous cell type.
Gene expression profile. Determination of the gene expression
profile of the 15 Sri Lankan patients, by hybridizing the cDNA
from the pair-wise normal and tumor samples to the 35k
human oligo microarray slides, resulted in a set of 263 genes
found as differently expressed between tumors and normal
controls. Of these, 190 (72%) genes (Table IIIA) were found
as upregulated and 73 (28%) (Table IIIB) were found as
downregulated.
Since there are many genes reported as differentially
expressed in OSCCs, we searched the Cancer Genome
Anatomy Project (CGAP, http://cgap.nci.nih.gov/) for genes
related to head and neck cancer, by using the Gene Library
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Table II. List of the probes for the genes analyzed by QRT-PCR.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
QRT-PCR probes
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene Assay ID Reporter sequence
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MMP1 Hs00233958_m1 TAAAGACAGATTCTACATGCGCACA
COL4A1 Hs00266237_m1 CCTCCAGGCCTCCCTGTACCTGGGC
GJA1 Hs00748445_s1 GACCAGTGGTGCGCTGAGCCCTGC
HAS3 Hs00193436_m1 TGGACTACATCCAGGTGTGCGACTC
ANGPTL4 Hs00211522_m1 CTGCACCGGCTGCCCAGGGATTGCC
CD47 Hs00179953_m1 GGCGTGCTGCGGATCAGCTCAGCTA
BPIL1 Hs00257918_m1 AGCATTGAGCTACGTGTCTGAAATT
WFDC2 Hs00196109_m1 CACCCTAGTCTCAGGCACAGGAGCA
S100A1 Hs00196704_m1 CCAGGCCAACCGTGCACTGCTGCAA
ACTB Hs99999903_m1 GCCTCGCCTTTGCCGATCCGCCGCC
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 1. Hierarchical clustering of the 263 genes found as differentially expressed between tumors and normal controls and their possible correlation to the
patients clinicopathological data.
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Table IIIA. Genes upregulated in tumor versus normal controls.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Adhesion associated genes
Cytokeratin 6A KRT6A H300014335 19.452
Keratin 17 KRT17 H200000678 14.011
Collagen I, alpha 1 COL1A1 H300015580 8.804
Periostin, osteoblast specific factor POSTN H300000923 8.632
Collagen IV, alpha 1 COL4A1 H200012184 7.971
Chloride channel CLCA2 H200015766 6.891
Odd Oz/ten-m homolog 2 ODZ2 H200008152 6.394
Hyaluronan synthase 3 HAS3 H200007172 6.024
Keratin 5 KRT5 H300019235 5.745
Myosin IB MYO1B H200012339 5.382
Ladinin 1 LAD1 H200002708 4.909
Serine proteinase inhibitor SERPINH1 H200001857 4.709
Thy-1 cell surface antigen THY1 H200012556 4.017
Molecule interacting with Rab13 MIRAB13 H300008711 3.977
Bicaudal D homolog 2 (Drosophila) BICD2 H200019300 3.578
CD47 antigen CD47 H200006967 3.317
Epithelial protein lost in neoplasm beta EPLIN H200001929 3.263
Development and differentiation enhancing factor 1 DDEF1 H200001924 3.076
Osteonectin SPARC H200011770 3.027
Actinin, alpha 1 ACTN1 H200012175 2.915
Dipeptidyl-peptidase 3 DPP3 H300022630 2.702
Hypothetical protein similar to actin ARPC5L H200018870 2.561
CD 44 antigen CD44 H300019814 2.542
Eukaryotic translation initiation factor 4A EIF4A1 H200012822 2.399
Plectin 1 PLEC1 H200006713 2.302
Integrin, beta 1 ITGB1 H300017353 2.207
Actin, gamma 1 ACTG1 H300006234 2.138
Tropomyosin 4 TPM4 H300013721 2.088
Angiogenesis
Matrix metalloproteinase 1 MMP1 H200007011 20.586
Matrix metalloproteinase 3 MMP3 H200007019 7.764
Plasminogen activator, urokinase PLAU H200006377 7.280
Endothelial cell growth factor 1 ECGF1 H200005893 7.054
Hexabrachion TNC H200009494 6.792
Interleukin 8 IL8 H200000156 5.645
Angiopoietin-like 4 ANGPTL4 H300021145 4.930
Jagged 1 JAG1 H300002958 4.773
Tryptophanyl-tRNA synthetase WARS H300012785 4.845
Hypoxia-inducible factor 1, alpha subunit HIF1A H200014761 2.620
Apoptosis
Caspase 1 CASP1 H200000628 7.589
Cofilin 1 (non-muscle) CFL1 H200008422 2.388
Cell-cell signaling
Interferon, alpha-inducible protein (clone IFI-15K) G1P2 H300006942 18.761
Interferon, alpha-inducible protein 27 IFI27 H200017325 8.509
Connexin 43 GJA1 H200005947 3.940
Cerebral cavernous malformation 2 CCM2 H200001861 2.626
Protein arginine methyltransferase 1 PRMT1 H300019121 2.458
Cell growth regulation
Solute carrier family 16 SLC16A1 H200006037 7.932
Bone marrow stromal cell antigen 2 BST2 H200012083 7.175
Serpin peptidase inhibitor SERPINB5 H300020178 6.169
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Table IIIA. Continued.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Caveolin 2 CAV2 H200013312 4.587
N-myc (and STAT) interactor NMI H300001976 4.525
Guanylate binding protein 2 GBP2 H200007999 4.412
Retinol binding protein 1 RBP1 H300001638 4.261
Basonuclin 1 BNC1 H300005994 4.252
Breast cancer metastasis suppressor 1 BRMS1 H300002128 3.891
RAB31, member RAS oncogene family RAB31 H200015253 3.864
EBNA1 binding protein 2 EBNA1BP2 H300005177 3.554
Caveolin 1 CAV1 H200005908 3.459
Polo-like kinase 2 PLK2 H300012787 3.348
Karyopherin alpha 2 KPNA2 H300007884 3.317
Stratifin SFN H300006188 3.275
Ribosomal protein S6 kinase RPS6KB2 H300007163 2.963
Non-metastatic cells 1 NME1 H200012135 2.963
Proliferation-associated 2G4 PA2G4 H300010406 2.875
Proteasome (prosome, macropain) 26S subunit PSMD1 H200000856 2.782
Exostoses (multiple) 2 EXT2 H200006075 2.593
Suppressor of G2 allele of SKP1 SUGT1 H200001007 2.354
RNA binding motif RBMS1 H300004002 2.255
Nitric oxide synthase interacting protein NOSIP H300022154 2.188
Immune response
Ig gamma-4 chain C region IGHG4 H300000934 10.716
Guanylate binding protein 1 GBP1 H200005495 9.735
2'-5'-oligoadenylate synthetase 2 OAS2 H300002591 8.434
Transporter 1, ATP-binding cassette TAP1 H300021278 5.455
Cathepsin C CTSC H300018822 4.684
Interferon, alpha-inducible protein G1P3 H200016555 4.436
Proteasome activator subunit 2 PSME2 H300007599 3.071
Apolipoprotein L, 3 APOL3 H200015760 3.048
Interferon induced transmembrane protein 2 IFITM2 H300004907 2.941
Tumor necrosis factor, alpha-induced protein 1 TNFAIP1 H200006250 2.933
Integral to membrane
Leucine-rich repeat-containing protein 8A LRRC8 H200008145 3.525
Intracellular signaling
Rag C protein RRAGC H200011726 3.678
Ras homolog gene family, member D RHOD H200002449 3.101
Diacylglycerol kinase DGKZ H200017225 2.975
Cornichon homolog 4 CNIH4 H300011960 2.943
Intracellular transport
Tubulin beta-5 TUBB6 H200017078 3.826
Nuclear transport factor 2 NUTF2 H300010247 2.337
Metabolism
Cathepsin L2 CTSL2 H200010239 5.169
Similar to glucosamine-6-sulfatases SULF2 H200004653 5.082
GM2 ganglioside activator protein GM2A H200009479 4.964
Selenoprotein X, 1 SEPX1 H200017458 3.870
Carbohydrate (N-acetylglucosamine-6-O) CHST2 H200001687 3.864
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Table IIIA. Continued.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Heat shock 105 kDa/110 kDa protein 1 HSPH1 H300019008 3.845
Prion protein (p27-30) PRNP H200005977 3.688
Thioredoxin-like 5 TXNL5 H200005936 3.497
Homo sapiens cDNA FLJ30135 fis, clone BRACE2000061 BLOC1S2 H200004282 3.230
Small nuclear ribonucleoprotein polypeptide G SNRPG H300006350 3.104
Adenosine kinase ADK H200010643 3.042
Mitochondrial ribosomal protein L15 MRPL15 H200002720 2.947
Heat shock 70 kDa protein 4 HSPA4 H300022500 2.895
Mitochondrial ribosomal protein L17 MRPL17 H200001870 2.811
Small nuclear ribonucleoprotein polypeptide A' SNRPA1 H300000296 2.670
Similar to peptidylprolyl isomerase (cyclophilin)-like 1 PPIL1 H300000902 2.664
Prefoldin subunit 2 PFDN2 H200009859 2.650
Small nuclear ribonucleoprotein polypeptide B'' SNRPB2 H200006957 2.626
Chaperonin containing TCP1, subunit 5 (epsilon) CCT5 H200000420 2.578
Mitochondrial ribosomal protein L14 MRPL14 H300010300 2.545
Similar to peptidylprolyl isomerase (cyclophilin)-like 1 PPIL1 H300002507 2.499
Peptidylprolyl isomerase A (cyclophilin A) PPIA H300005405 2.382
LSM1 homolog, U6 small nuclear RNA associated LSM1 H200011772 2.289
Mitochondrial ribosomal protein S12 MRPS12 H200001864 2.273
Nucleolar protein family A, member 3 NOLA3 H300001534 1.955
Proteasome (prosome, macropain) 26S subunit PSMC1 H200000913 1.858
Oncogene
V-Ha-ras Harvey rat sarcoma viral oncogene homolog HRAS H300018518 3.298
Met proto-oncogene (hepatocyte growth factor receptor) MET H300013056 3.141
V-jun sarcoma virus 17 oncogene homolog (avian) JUN H200006516 1.926
Signal transduction
Signal transducer and activator of transcription 2, 113 kDa STAT2 H300010660 4.436
Lymphocyte antigen 6 complex, locus E LY6E H200006433 3.491
Tyrosine kinase, non-receptor, 2 TNK2 H300022337 2.292
Transcriptional regulation
Superoxide dismutase 2, mitochondrial SOD2 H200018923 4.335
Interferon regulatory factor 7 IRF7 H300021511 3.581
BolA-like protein 2 BOLA2 H300001390 3.158
SUB1 homolog (S, cerevisiae) SUB1 H300000824 3.127
BTB and CNC homology 1, basic leucine zipper 
Transcription factor 1 BACH1 H200013953 2.967
Ubiquitin cycle
Ubiquitin-conjugating enzyme E2S UBE2S H300007235 4.858
Proteasome (prosome, macropain) subunit, alpha type, 1 PSMA1 H200006899 3.307
Proteasome (prosome, macropain) subunit, alpha type, 4 PSMA4 H200016300 3.206
Proteasome (prosome, macropain) subunit, beta type, 2 PSMB2 H300007846 3.037
Ring finger protein 149 RNF149 H300001827 2.706
Ubiquity-conjugating enzyme E2L 3 UBE2L3 H300004594 2.410
Ring-box 1 RBX1 H200017552 2.236
Genes with other functions
SRY (sex determining region Y)-box 20 SOX15 H200010702 6.417
BA13B9,3 (Novel protein similar to KRT8) KRT8L1 H300008020 4.819
TLH29 protein precursor FAM14A H200010658 4.498
Hematological and neurological expressed 1 HN1 H300005778 4.229
Nuclear RNA helicase, DECD variant of DEAD box family DDX39 H200018834 3.966
HSPC160 protein ORMDL2 H200002233 2.948
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Table IIIA. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CDW92 antigen CDW92 H200008388 3.832
Brix domain containing 2 BXDC2 H300020946 2.822
Solute carrier family 7, member 5 SLC7A5 H200014300 2.783
Signal peptidase complex subunit 3 homolog SPCS3 H200004559 2.667
Protein phosphatase 1, regulatory (inhibitor) subunit 14B PPP1R14B H300013966 2.471
Coiled-coil-helix-coiled-coil-helix domain containing 1 CHCHD1 H300005351 2.329
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 21 DDX21 H200007834 1.996
Genes with unknown function
Epithelial stromal interaction 1 (breast) EPSTI1 H200019973 7.766
Family with sequence similarity 83, member A FAM83A H200016387 6.537
Hypothetical protein MGC4677 LOC541471 H300002112 4.692
Melanoma-derived leucine zipper, extra-nuclear factor MLZE H200013079 4.471
Hepatitis delta antigen-interacting protein A CCDC85B H200005619 3.048
Family with sequence similarity 49, member B FAM49B H300020526 2.927
Chromosome 19 open reading frame 22 C19orf22 H200001829 2.891
COBW domain containing 1 CBWD1 H300020976 2.690
Hypothetical protein FLJ10350 RPRC1 H200008278 2.685
KIAA0842 protein KIAA0842 H200005962 2.680
Hypothetical protein MGC22793 MGC22793 H300005475 2.312
TPA regulated locus TPARL H200015568 2.186
Unknown - H300016521 16.121
Unknown - H300000399 11.819
Unknown - H300016456 10.856
Unknown - H300022261 9.555
Unknown - H300009062 6.931
Hypothetical gene supported by AK023162 - H200001742 6.817
Unknown - H300014044 6.517
Unknown - H300008061 5.898
Unknown - H300006085 5.625
Unknown - H300000084 5.119
Q5T7K4_HUMAN - H300002726 4.300
Hypothetical protein MGC4677 - H300002113 4.006
Unknown - H200001872 3.982
FLJ46072 - H300002815 3.688
Unknown - H300000271 3.266
Unknown - H300006679 2.888
Unknown - H300021607 2.751
Unknown - H300003367 2.620
Unknown - H300008569 2.549
Hypothetical protein DKFZp586I1420 - H200011821 2.523
Unknown - H300001105 2.479
Unknown - H300000638 2.439
Unknown - H300012353 2.439
Unknown - H300000861 2.325
Unknown - H300009853 2.256
Unknown - H300001828 2.242
Unknown - H300022664 2.216
Unknown - H300003465 2.196
13kDa differentiation-associated protein - H200004675 2.162
Unknown - H300009555 2.158
Unknown - H300009420 2.045
Unknown - H300008478 1.987
Unknown - H200003368 1.971
Unknown - H300003763 1.867
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Summarizer tool and the following search criteria: Organism:
Homo sapiens; Library Group: CGAP Libraries; Tissue type:
Head and neck; Library Preparation: Any; Tissue Histology:
Cancer; Library Protocol: Any. We compared the differentially
expressed genes found in our study with the search results
(2,500 genes involved in head and neck cancer) and found that
66 of the genes [such as COL4A1, COL1A1, PLAU, MMP1,
MMP3, ITGB1, SPARC (upregulated), SLPI, EEF1A1 and
KRT19 (downregulated), among others] matched results from
the CGAP search. These genes have also been reported in
previous studies related to gene expression profiles in oral
cancer (14). The genes that were neither listed in the CGAP
nor previously reported in OSCCs included CD47, UBE2L3,
RPS6KB2, APOL3, RRAGC (upregulated), AZGP1, CLN3 and
XBP1 (downregulated). To obtain information on gene
function, we searched the CGAP database using the Gene
Finder tool and the Gene Ontology Browser. Genes of known
function (192 of the 263 genes) were found to be related to
cellular processes like cell adhesion, cell signaling,
angiogenesis, metastasis and metabolism.
To determine the significant changes related to the
biological systems, a GO DAG analysis was performed, which
resulted in the following terms: transcription regulator activity,
structural molecule activity, intracellular signaling cascade,
cytoskeleton and signal transduction.
Hierarchical clustering. Hierarchical clustering of the 15
samples using the 263 genes found, resulted in several
subgroups (Fig. 1). Sample number 1 and 11 (verrucous SCC
and an advanced SCC), did not cluster with any of the other
cases. The remaining cases clustered in several subgroups,
such as samples with tumors of different TNM status, BQ
chewers and non-BQ chewers, smokers, non-smokers, drinkers
and non-drinkers. Interestingly however, tumors of stage three
and four showed a tendency to group together, although one of
the samples (number nine, a tumor of stage 2) clustered with
these tumors, which might indicate a tendency towards
developing an aggressive behavior though presented as
stage 2. Although this is an interesting observation, analysis
of additional cases is necessary. All patients were smokers
and/or BQ chewers with varying types of alcohol habits. The
two non-BQ chewers grouped differently, although their
tumors were of stage 2. One of the samples (non-betel quid
user) clustered in a large subgroup, while the other separated
from the rest in a subgroup on a higher level. Patient number 2,
diagnosed with a stage 1 tumor, was also distinguishable from
the other patients and grouped separately.
KEGG pathway analysis. The KEGG pathway analysis
(performed with the 192 genes with known functions), showed
six pathways where a significant number of the genes found
were included. The predominant pathways found were cell
communication and integrin-mediated cell adhesion (Fig. 2)
where 10 and 11 genes were represented, respectively.
Quantitative real-time RT-PCR. Gene expression profile was
validated by quantitative reverse transcription for nine genes.
We used ß-actin for normalization and determination of the
results. A good correlation was found between the microarray
data and the RT-PCR results (Fig. 3).
Discussion
In this study, we analysed gene expression profile in 15 cases
of OSCCs from Sri Lanka and correlated the findings to the
clinicopathological parameters. We identified 263 genes as
differentially expressed between tumors and normal controls
where 190 (72%) were upregulated and 73 (28%) were
downregulated. Of the genes found, 192 (73%) were of known
functions, where 66 of these genes (34%) (such as COL1A1,
COL4A1, MMP1, TNC and PLAU) were previously reported
in the CGAP database (http://cgap.nci.nih.gov/). The 192
known genes were found to be implicated in cellular processes
like cell growth, cell proliferation, cell signaling and
angiogenesis that were suggested to play an important role in
oral tumorigenesis (9,22,23). We selected nine genes
(COL4A1, GJA1, MMP1, HAS3, CD47, ANGPTL4, S100A1,
BPIL1 and WFDC2) and verified their expression with
quantitative real-time PCR. Both up- and downregulated genes
were selected, as well as genes that were either previously
reported or not reported in OSCCs. 
COL4A1, found as upregulated in this study, is the main
constituent of the extracellular matrix (ECM) and the
basement membrane (BM) (24). It has been suggested that
increased collagen synthesis is related to the use of betel quid
and oral submucous fibrosis - a precursor condition to oral
cancer (25). Tsai et al (26) studied gene expression profile in
oral cancers from betel quid chewers in Taiwan and reported
an increase in COL4A1 expression. Other studies in OSCCs
have also reported an increased expression of this gene (14). In
Taiwan, BQ is used without tobacco, but in Sri Lanka tobacco
is commonly added to BQ (2). Our findings of increased
COL4A1 expression in the biopsies examined from Sri Lanka
are in agreement with the findings from Taiwan, suggesting a
possible role of BQ in the upregulation of COL4A1. These
results indicate that COL4A1 might be considered as a possible
biomarker in BQ related lesions, but further confirmatory
studies are needed. 
HAS3, showing increased expression in this study, encodes
the enzyme hyaluronan synthase 3, one of the three enzymes
involved in synthesis of hyaluronan, an ECM related glyco-
saminoglycan associated with proliferation and migration (27).
Hyaluronan has been found to interact with CD44 (found as
upregulated in our study) and was suggested to be implicated
in tumor growth and metastasis. There are no reports of
HAS3 in relation to oral cancer and this is also the case with
CD47, a gene encoding a cell adhesion protein (28).
We detected an upregulation of ANGPTL4 (angiopoietin-
like 4, previously not reported in oral cancer), a gene induced
by hypoxia and grouped under angiogenesis-related genes
(pro-angiogenic) (29). MMP1 is a metalloproteinase involved
in the breakdown of the ECM during angiogenesis, invasion
and metastasis (30,31). Our study showed upregulation of
MMP1, which is in agreement with other experiments in oral
cancer (14,26,32). GJA1 (Connexin43, a gap junction
constituent involved in intercellular communication) (33),
has been suggested to play an important role in the regulation
of cell growth and is associated with cancer development
(33). Our findings of upregulation of this gene are supported
by one other previous study on OSCC (34). S100A1, found as
downregulated in our study, is a member of the S100 gene
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Table IIIB. Genes downregulated in tumor versus normal controls.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Apoptosis
Phospholipid scramblase 3 PLSCR3 H300022882 -3.103
Ceroid-lipofuscinosis, neuronal 3, juvenile CLN3 H300012300 -2.188
Adhesion associated genes
Statherin STATH H200004368 -101.425
Alpha-2-glycoprotein 1, zinc AZGP1 H200000021 -41.885
Keratin 19 KRT19 H200008573 -15.716
Cysteine-rich secretory protein 3 CRISP3 H200005086 -12.501
Mucin 5, subtype B, tracheobronchial MUC5B H300022927 -9.895
Keratin 7 KRT7 H200003337 -4.630
Cell growth regulation
Putative cytokine high in normal-1 HIN-1 H200005487 -17.842
Tetraspan 1 TSPAN1 H200004450 -9.837
N-myc downstream-regulated gene 2 NDRG2 H200015807 -4.738
Immune response
Secretory leukocyte protease inhibitor SLPI H200016308 -9.310
Immunoglobulin J polypeptide IGJ H300003753 -4.258
X-box binding protein 1 XBP1 H200013682 -3.134
Intracellular signaling
S100 calcium binding protein A1 S100A1 H200009536 -3.485
Metabolism
Phosphoglycerate dehydrogenase PHGDH H300006924 -5.323
Carbonyl reductase DCXR H200001845 -2.262
Eukaryotic elongation factor 1 alpha 1 EEF1A1 H300022640 -2.075
Eukaryotic translation elongation factor 1 gamma EEF1G H300009473 -1.997
Ribosomal protein L22 RPL22 H300009237 -1.929
Similar to ribosomal protein L13a  LOC387841 H300002118 -1.672
Ribosomal protein L13 RPL13 H300021124 -1.565
Proteolysis
WAP four-disulfide core domain 2 WFDC2 H300022511 -27.078
Kallikrein 11 KLK11 H200005275 -4.398
ATG4 autophagy related 4 homolog B APG4B H300003574 -2.167
Signal transduction
Calcitonin-related polypeptide, beta CALCB H200017136 -15.155
Protein FAM3D precursor FAM3D H200005421 -10.170
Tetraspanin 13 TSPAN13 H300011863 -5.236
GNAS complex locus GNAS H300022096 -2.367
Transcriptional regulation
Zinc finger protein 253 ZNF253 H300008475 -2.138
Genes with other functions
Hypothetical protein dJ726C3.2 BPIL1 H200016425 -196.506
Proline rich 4 (lacrimal) PRR4 H300001196 -41.384
Mucin 7, salivary MUC7 H200011272 -37.298
Trefoil factor 3 (intestinal) TFF3 H300004783 -20.952
Transcobalamin TCN1 H200000515 -9.862
Olfactory receptor 5T2 OR5T2 H300003770 -8.712
Hemoglobin, alpha 1 HBA1 H200016940 -8.655
Crumbs homolog 3 (Drosophila) CRB3 H200013695 -8.483
Hemoglobin, beta HBB H300022339 -5.687
Defensin, beta 1 DEFB1 H200004191 -4.573
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family, coding for Ca2+-binding proteins, suggested to play an
important role in cancer progression (35). Downregulation of
S100A1 has been reported in another study on head and neck
cancer (36). WFDC2, Wap four-disulfide core domain 2
(found as downregulated in this study), is a gene encoding a
protease inhibitor and has been suggested as a tumor
biomarker in ovarian carcinoma (37).
OSCC is a major health problem related to betel quid use
and smokeless tobacco habits in developing countries, albeit
there are few studies focusing on gene expression profile of
oral cancers from these countries. There are several studies
performed in OSCCs from western countries (14,32,38-40),
and some of the genes found in our study to be differentially
expressed correlate with findings from western countries.
These include in particular COL4A1, COL1A1, MMP1, PLAU,
SPARC, TNC and KRT19, with MMP1 and PLAU as the most
frequent genes. MMPs have been described as possible
biomarkers of invasion and metastasis in oral cancers (30),
which might also apply for the cases examined herein. PLAU
has been suggested to be implicated in enhanced cell
proliferation and migration (41) and as a prognostic marker
for relapse-free survival of OSCCs, together with its receptor
uPAR (42). SPARC, or osteonectin, is also implicated in ECM
breakdown (43) and has been reported to be associated with
tumor progression and metastasis (44). This protein was
previously reported in two studies from Sudan, where the use
of oral snuff (toombak) is common (45,46). The frequent
reports of the ECM related genes in association with OSCCs
might suggest that ECM breakdown is an important process in
oral carcinogenesis. This is supported by our finding of cell
adhesion as one of two predominant biological pathways.
MMP1 is related to COL4A1, which is an important ECM
constituent, suggesting that an increase in COL4A1 expression
might be related to betel quid usage as suggested by others
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Table IIIB. Continued.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Average
Gene name/function Gene symbol Oligo_ID fold change
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Hypothetical protein FLJ40504 FLJ40504 H300004165 -3.751
Olfactory receptor 8G5 OR8G5 H300006949 -3.561
H2A histone family, member L HIST1H2AC H200003862 -3.446
Lysozyme (renal amyloidosis) LYZ H200015514 -3.077
Transmembrane emp24 protein transport domain containing 3 TMED3 H200008352 -2.719
Reticulon 3 RTN3 H300008519 -2.583
Chromosome 1 open reading frame 8 C1orf8 H200002003 -2.359
ATP synthase, H+ transporting, mitochondrial F0 complex,
subunit c (subunit 9), isoform 2 ATP5G2 H200010315 -2.216
Genes with unknown function
Hypothetical protein LOC124220 LOC124220 H200011403 -180.985
Anterior gradient 2 homolog (Xenepus laevis) AGR2 H200010467 -37.251
Dpy-like 2 protein DPY19L2 H300011031 -27.669
Chromosome 4 open reading frame 7 C4orf7 H300008107 -10.921
La ribonucleoprotein domain family, member 2 LARP2 H300022914 -4.066
KIAA1693 NBPF1 H300006550 -3.177
Glioma tumor suppressor candidate region gene 2 GLTSCR2 H300001487 -2.023
Unknown - H300007292 -98.978
Unknown - H300015187 -24.882
MGC34829 protein - H300004686 -23.621
Hypothetical protein DKFZp586L111 - H200019198 -22.175
Unknown - H300011211 -18.810
Hypothetical protein LOC90113 - H200019881 -13.858
PRO1848 - H200007208 -6.556
Hypothetical protein DKFZp781I24108 - H300001302 -4.690
Unknown - H300008514 -4.604
Unknown - H300005667 -4.363
Unknown - H300008538 -4.245
Unknown - H300010322 -3.754
Unknown - H300017074 -2.986
Homo sapiens, clone IMAGE:3633225, mRNA - H200020471 -1.892
Unknown - H300009486 -1.839
Unknown - H300004908 -1.783
Unknown - H300002725 -1.714
Unknown - H300000309 -1.644
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Figure 2. KEGG analysis illustrating cell communication (2A) and focal adhesion molecules (2B) pathways.
A
B
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(25,47,48). Since PLAU may also be related to COL4A1
through ECM breakdown, MMP1, COL4A1, PLAU and
SPARC might be suggested as possible biomarkers for OSCCs
associated with betel quid chewing as a causative factor. The
fact that these four genes have been consistently reported in
relation to cancers of the oral cavity in Asian populations
might indicate a possible relationship between their increased
expression and betel quid usage.
Gene expression profiling not only offers the possibility of
finding specific genes differentially expressed between cancer
and normal tissue, but individual samples or subgroups can
also be distinguished by determining the general profile of
each sample. In our study, hierarchical clustering of the
analyzed samples showed several subgroups, with the
exception of one case diagnosed with a verrucous SCC - a
tumor related to smokeless tobacco that is usually less
ONCOLOGY REPORTS  18:  1061-1075,  2007 1073
Figure 3. Association between the microarray hybridization and the QRT-PCR data. Results are presented here for COL4A1 (A), ANGPTL4 (B) and S100A1
(C). The light columns, RT-PCR data; the dark columns, microarray data.
A
B
C
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aggressive compared to other OSCCs (39,40,49). Another
sample also differed from the other cases by grouping
separately, and this was the only stage 1 tumor among the 15
cancers analyzed. We observed a large subgroup of samples
with tumors predominately at stage 3 and 4, which might
suggest that advanced tumors have a common gene expression
profile compared with tumors at stage 1 and 2. Interestingly
however, one other stage 2 tumor clustered with tumors of
stage 3 and 4, suggesting a gene expression profile in this
sample that is similar to advanced tumors. Relevance of these
observations needs to be verified in larger samples. Other
OSCC studies using gene expression profiles have elucidated a
way of distinguishing metastasizing tumors from non-
metastasizing tumors (14). Data of this kind may be valuable
in predicting the outcome and risk of metastasis of different
tumors, in addition to the traditional tumor classification
criteria. Identification of aggressive tumors also offers the
possibility of describing individual therapeutic approaches and
improved treatment planning.
Further studies will therefore be necessary to confirm our
findings, which might lead to a better understanding of the
molecular basis of cancer development and tumor progression,
particularly in relation to BQ induced oral cancers.
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